These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 19620852)

  • 1. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
    Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
    Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A.
    Kranz G; Sycha T; Voller B; Kranz GS; Schnider P; Auff E
    Neurology; 2008 Jan; 70(2):133-6. PubMed ID: 18180443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.
    Birklein F; Walther D; Bigalke H; Winterholler M; Erbguth F
    Ann Neurol; 2002 Jul; 52(1):68-73. PubMed ID: 12112049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
    Rollnik JD; Wohlfarth K; Dengler R; Bigalke H
    Neurol Clin Neurophysiol; 2001; 2001(3):2-4. PubMed ID: 12396862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.
    Göschel H; Wohlfarth K; Frevert J; Dengler R; Bigalke H
    Exp Neurol; 1997 Sep; 147(1):96-102. PubMed ID: 9294406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A.
    Voller B; Moraru E; Auff E; Benesch M; Poewe W; Wissel J; Müller J; Entner T; Bigalke H; Schnider P
    Mov Disord; 2004 Aug; 19(8):943-7. PubMed ID: 15300661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.
    Kessler KR; Benecke R
    Mov Disord; 1997 Jan; 12(1):95-9. PubMed ID: 8990060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.
    Mathevon L; Declemy A; Laffont I; Perennou D
    Ann Phys Rehabil Med; 2019 Jul; 62(4):241-251. PubMed ID: 30980953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure.
    Schulte-Baukloh H; Bigalke H; Miller K; Heine G; Pape D; Lehmann J; Knispel HH
    Int J Urol; 2008 May; 15(5):407-15; discussion 415. PubMed ID: 18452456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
    Brin MF; Comella CL; Jankovic J; Lai F; Naumann M;
    Mov Disord; 2008 Jul; 23(10):1353-60. PubMed ID: 18546321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection.
    Schulte-Baukloh H; Bigalke H; Heine G; Pape D; Stuerzebecher B; Miller K; Knispel HH
    Urology; 2007 Mar; 69(3):575.e13-5. PubMed ID: 17382174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower facial contouring with botulinum toxin type A.
    Tartaro G; Rauso R; Santagata M; Santillo V; Itro A
    J Craniofac Surg; 2008 Nov; 19(6):1613-7. PubMed ID: 19098563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.